Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes

Abstract

This invention is directed to methods for prevention of infections by highly pathogenic viruses by applying to the nasal mucous membranes topical preparations comprising the broad-spectrum antimicrobial agent povidone-iodine.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]The present application is a Divisional application of U.S. application Ser. No. 16 / 925,740, filed Jul. 10, 2020, which is a United States national stage entry of International Patent Application No. PCT / AU2020 / 050586, filed Jun. 10, 2020, which claims priority to Australian patent application no. 2020900489, filed Feb. 20, 2020, and Australian patent application no. 2019902006, filed Jun. 10, 2019, the contents of each of which are incorporated herein by reference in their entirety.FIELD OF THE INVENTION[0002]This invention is directed to methods for prevention of infections by highly pathogenic viruses by applying to the nasal mucous membranes topical preparations comprising the broad-spectrum antimicrobial agent povidone-iodine.BACKGROUND OF THE INVENTION[0003]Diseases caused by, generally zoonotic, highly pathogenic viruses are of increasing concern to health authorities. Prominent recent examples are the outbreaks of diseases caused ...

AI Technical Summary

Benefits of technology

The patent involves methods for using a preparation called PVP-I to reduce the risk of spreading or getting infected with HP viruses. It would also include using it to protect people who may be exposed to HP viruses or who are at risk of infection because of previous exposure.

Problems solved by technology

In some cases, such as novel, emergent influenza viruses and SARS-CoV-2, they have the potential to become pandemic, causing significant societal impact, large numbers of deaths and major challenges for frontline healthcare workers who are at risk of contracting the virus.

Because of these factors, and other factors, such as environmental conditions and training, standard barrier protection procedures, such as hand hygiene and personal protective equipment (PPE) such as gloves, masks, eye protection and respirators, may not be sufficient to prevent infection of healthcare workers from Ebola.

Meanwhile, those exposed without PPE, such as family members, are at high risk of infection.

Like Ebola, pandemic influenza is a potentially fatal illness that continues to cause global concern.

Existing antiviral agents such as zanamivir and oseltamivir have been of limited effectiveness in treating AIV infections, because by the time the patient presents it is generally too late in the infection.

Efforts are also underway to develop vaccines but no effective vaccine for all pandemic strains has become available to date and, despite many attempts, no universal vaccine has been developed.

Many patients develop pneumonia, which is the principal cause of mortality.

However, a wide clinical spectrum of MERS-CoV infection has been reported, ranging from asymptomatic infection to acute upper respiratory illness, and rapidly progressive pneumonitis, respiratory failure, septic shock and multi-organ failure resulting in death.

However, such protections may not be fully effective and may not be available to all healthcare workers and others who may be exposed.

This filtration mechanism arguably results in accumulation of viruses and bacteria in the nasal passages where they are able to proliferate, requiring the body to mount an immune defence to counter the burgeoning viral load.

The escalating viral load within the nasal passages increases the risk of the virus finding its way into the lungs, such as in MERS and SARS, or spreading systemically through the body.

Images